Binding of E-cadherin on PDX tumor cells to CD103+ CD8+ TRM cells may sequester these TILs within the tumor implant, and the expression of E-Cadherin by EpCAM+ tumor cells was not affected by trametinib treatment (Figure 6A). Here, CD8A is linked to neoplasm.